A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Solid Tumors|HER2-positive Breast Cancer|HER2-positive Colorectal Cancer|HER2-positive Gastroesophageal Cancer|HER2-positive Endometrial Cancer
Interventions: DRUG: BDC-1001|DRUG: Nivolumab
Sponsor: Bolt Biotherapeutics, Inc.
Collaborators: Bristol-Myers Squibb